ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Modulating T Cell Migration in the Postischemic Liver: Hepatic Stellate Cells as New Therapeutic Target?

A. Khandoga, K. Mende, M. Rentsch, J. Reifart

Department of Surgery-Grosshadern, University of Munich, Munich, Germany

Meeting: 2013 American Transplant Congress

Abstract number: A734

Related Abstracts
  • Hepatic Stellate Cells Inhibit T Cells Through Active TGFβ1 from a Cell-Surface-Bound Latent TGFβ1/GARP Complex
  • Hepatic Stellate Cells Directly Inhibit B Cells Via PD-L1

Background: CD4+ T cells play a critical role during hepatic ischemia-reperfusion (I/R) injury although the mechanisms of their migration in the postischemic liver in remain unclear. Recently, T cells were suggested to colocalize with hepatic stellate cells (HSCs) in the liver during viral hepatitis. Here, we answered the question i) whether HSCs interact with T cells during I/R of the liver, and ii) whether modulation of HSC activity is protective against T cell-dependent I/R injury.

Methods: Migration of freshly isolated and fluorescence-labeled CD4+ T cells was analyzed using intravital videofluorence microscopy in sham-operated mice and in three different groups mice after I/R (90min/120min, n=7 each group). Sinusoidal perfusion and liver enzyme activities were determined as markers of I/R injury.

Results: T cell-HSC interactions were visualized in vivo after infusion of fluorenscence-labeled CD4+ T cells into Cx3CR1 mice (mice exhibiting GFP-labeled HSCs) after I/R. Since the activation of HSC is controlled by endocannabioid receptors CB-1 and CB-2, we infused either the CB-2 agonist JWH-133 (0.2 mg/kg) to reach HSC depletion or the CB-1 agonist ACPA (1 mg/kg) to activate HSC to mice after I/R. Hepatic I/R induced CD4+ T cell recruitment in sinusoids (8.1±0.5/acinus, p<0.05 vs. 2.8±0.2/acinus in sham). In contrast, the HSC deactivation with JWH-133 significantly attenuated the CD4+ T cell recruitment in the postischemic liver (3.7±0.6/acinus) and reduced I/R injury (AST: 1996±261, AST: 2159±323U/L, p<0.05) as compared to the vehicle-treated group (5648±540 and 6480±521U/L, respectively). HSC hyperactivation via CB-1, however, did not affect T cell migration and even increased perfusion failure.

Conclusion: Our in vivo data suggest i) that CD4+ cells interact with HSC upon their migration into the hepatic parenchyma; ii) a selective depletion/deactivation of HSC reduces T cell-dependent I/R injury. Thus, HSC might represent a potential target for future therapeutic strategies against T cell-mediated I/R injury.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Khandoga A, Mende K, Rentsch M, Reifart J. Modulating T Cell Migration in the Postischemic Liver: Hepatic Stellate Cells as New Therapeutic Target? [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/modulating-t-cell-migration-in-the-postischemic-liver-hepatic-stellate-cells-as-new-therapeutic-target/. Accessed January 27, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.